Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29356405 | 0.89 | DGAT1 (0.47) | NOTUMKDM4EALDH1A1MAPK1TP53 | |
| SCHEMBL16595887 | 0.86 | NOTUM (0.51) | NOTUMKDM4EALDH1A1MAPK1TP53 | |
| SCHEMBL17303476 | 0.85 | NOTUM (0.58) | NOTUMKDM4EALDH1A1MAPK1TP53 | |
| SCHEMBL321724 | 0.84 | LMNA (0.61) | NOTUMKDM4EALDH1A1MAPK1TP53 | |
| SCHEMBL2161445 | 0.83 | LMNA (0.56) | NOTUMKDM4EALDH1A1MAPK1MAPT | |
| SCHEMBL31173853 | 0.83 | LMNA (0.56) | NOTUMKDM4EALDH1A1MAPK1MAPT | |
| SCHEMBL609355 | 0.82 | TP53 (0.68) | NOTUMKDM4EALDH1A1MAPK1TP53 | |
| SCHEMBL1019716 | 0.82 | NOTUM (0.59) | NOTUMKDM4EALDH1A1MAPK1TP53 | |
| SCHEMBL1364657 | 0.81 | AOC2 (0.58) | NOTUMKDM4EALDH1A1MAPK1TP53 | |
| SCHEMBL2401139 | 0.81 | NOTUM (0.53) | NOTUMKDM4EALDH1A1MAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580404-A2 | SULFONAMIDE APYRASE INHIBITORS | Texas Crop Science, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | claimed |
| WO-2024050041-A2 | SULFONAMIDE APYRASE INHIBITORS | TEXAS CROP SCIENCE (US) | 2024-03-07 | — | — | WO | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2590984-A1 | ANELLATED PYRIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-15 | — | — | EP | claimed |
| EP-2582705-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-24 | — | — | EP | claimed |
| WO-2012004206-A1 | ANELLATED PYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | claimed |
| WO-2011161009-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-29 | — | — | WO | claimed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3256218-B1 | A KDM1A INHIBITOR AND ITS USE IN THERAPY | IMAGO BIOSCIENCES INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12103921-B2 | Chemical compounds | PFIZER INC. (US) | 2024-10-01 | — | — | US | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| CN-1674892-A | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-0022078-B1 | PYRAZOLO-QUINOLINES, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | NOTUM 3385/4885KDM4E 3580/4885ALDH1A1 614/4885 |
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | APEH, ARSA, DNPEP | NOTUM 81/4885KDM4E 1929/4885ALDH1A1 1085/4885 |
| US-12103921-B2 | Chemical compounds | HBZ, HBB, HBS1L | NOTUM 4849/4885KDM4E 2745/4885ALDH1A1 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.